Core Outcomes for trials
The four core outcome domains that should be measured and reported in ALL eczema trials are:
- Clinician-reported signs
- Patient-reported symptoms
- Quality of Life
- Long-term control
All trials should measure the core domains and measure these using core outcome instruments (where available) as this will enable trials to be compared and combined in meta-analyses. However, the inclusion of core outcomes does not preclude the use of any additional domains, scales or instruments.
Clinical Signs - EASI
EASI
For clinical signs
Consensus Statement: Schmitt et al. 2014
Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema.
For more details on how to use the Core Outcome Set, read our
users' guide.
When referencing the Core Outcome Set, please
cite this paper:
The HOME core outcome set for clinical trials of atopic dermatitis Hywel C Williams, Jochen Schmitt, Kim S Thomas, Phyllis Spuls, Eric L Simpson, Christian J Apfelbacher, Joanne R Chalmers, Masutaka Furue, Norito Katoh, Louise A Gerbens, Yael A Leshem, Laura Howells, Jasvinder A Singh, Maarten Boars, HOME initiative. J Allergy Clin Immunol. 2022 Jun;149(6):1899-1911.doi: 10.1016\j.jaci.2022.03.017 EPub 2022 Mar 26
